|Bid||1.7000 x 1100|
|Ask||1.8300 x 900|
|Day's Range||1.6500 - 1.8000|
|52 Week Range||1.2600 - 6.8600|
|Beta (5Y Monthly)||2.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 09, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.67|
Subscribe to Yahoo Finance Plus to view Fair Value for ADAP
Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
If you want to know who really controls Adaptimmune Therapeutics plc ( NASDAQ:ADAP ), then you'll have to look at the...
Shares of the British cell therapy company Adaptimmune Therapeutics (NASDAQ: ADAP) are having one of their best days in several months today. To put this move into the proper context, the bellwether biotech indices -- the iShares Biotechnology ETF and the SPDR S&P Biotech ETF -- are both essentially flat for the day at the time of this writing. Adaptimmune's shares appear to be perking up in response to the buyout of fellow soft tissue cancer specialist Epizyme (NASDAQ: EPZM) earlier today.